FDAnews
www.fdanews.com/articles/184222-nice-recommends-against-opdivo-in-metastatic-bladder-cancer

NICE Recommends Against Opdivo in Metastatic Bladder Cancer

November 2, 2017

The U.K.’s National Institute for Health and Care Excellence issued a draft guidance recommending against routine NHS use of Opdivo (nivolumab) in metastatic urothelial carcinoma.

NICE said that while Bristol-Myers Squibb’s Opdivo had been studied in a clinical trial for this indication, it was not directly compared with other treatments, and it would be difficult to establish the drug’s clinical benefit versus current practice. It does, however, meet the criteria to be considered a life-extending end-of-life treatment.

A NICE committee estimated that Opdivo would cost approximately £76,000, or approximately $100,000, for each quality-adjusted life-year gained; more than generally considered acceptable for end-of-life care.

View today's stories